The diagnostic value of serum C-reactive protein/high-density lipoprotein in microvascular angina

The diagnostic value of serum C-reactive protein/high-density lipoprotein in microvascular angina | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article The diagnostic value of serum C-reactive protein/high-density lipoprotein in microvascular angina Wenxin Zhao, Lida Wang, Yongxu Cai, Xianfeng Zhao, Zhongyan Li This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4973475/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Objective This study aimed to explore the relation ship between the serum ratio of C-reactive protein (CRP) to high density lip opro tein cholesterol (HDL-C) with microvascular angina(MVA).It also aimed to evaluate the predictive value of serum CRP /HDL-C in relation to MVA. Methods The observation group consisted of 70 patients diagnosed with MVA ,while the control group included 68 patients with normal or minimal (< 50%) stenosis on coronary angiography, negative ECG exercise test and normal coronary blood flow randomly selected using a random number table method.Serum CRP,HCY,HDL-C and other relevant parameters were measured in both groups, with CRP /HDL-C calculated.Logistic regression analysis, and receiver operating characteristic (ROC) curve analysis were performed to identify independent risk factors for microvascular angina. Results CRP/HDL-C levels were significantly elevated in MVA patients with statistical significance (P < 0.001).The parameterswas identified as independent risk factor for predicting MVA occurrence.The results of ROC analysis indicated that CRP /HDL-C showed high predictive value for diagnosing MVA .The CRP/HDL-C had a higher area under the curve (AUC) for diagnosing microvascular angina compared to individual parameters ,with a statisticallysignificantdifference(P<0.05). Conclusions Elevated CRP /HDL-C levels can serve as positive predictors for diagnosing MVA.The parameters can enhance diagnostic accuracy and aid in the early identification of MVA patients.. C-reactive protein high density liptein cholesterol microvascular angina pectoris Figures Figure 1 Figure 2 1. Introduction Microvascular angina pectoris (microvascular angina, MVA) is a clinical syndrome [1] , Which is characterized by structural and functional abnormalities of anterior coronary arterioles, arterioles and capillaries. It is precisely because of these abnormalities in microvascular structure and function that MVA patients are at a significantly increased risk of major cardiovascular adverse events such as heart failure and acute coronary syndrome, so timely identification and intervention of MVA patients is crucial. At present, common methods for MVA diagnosis include invasive methods such as coronary angiography, intra-coronary Doppler blood flow guide wire, noninvasive methods such as cardiac magnetic resonance imaging, positron emission computed tomography imaging and single-photon emission computed tomography imaging [2] , But these inspection techniques are difficult to popularize, mainly because of their high cost and high technical requirements. Therefore, it is urgent to develop a simple, non-invasive and reliable serological diagnostic method. According to studies, the pathogenesis of MVA is closely related to the inflammatory response and dysfunction of coronary microvessels [3] 。C-reactive protein (C-reactive protein, CRP) is an acute time-phase inflammatory marker, and its level is positively correlated with the inflammatory status of the body, which can reflect the diagnosis and prognosis of coronary heart disease (coronary heart disease, CHD) to some extent [4] . High-density lipoprotein cholesterol (HDL-C) not only participates in cholesterol reverse, but also slows the progression of atherosclerosis through antioxidant, anti-inflammatory and improvement of endothelial cell function [5] . Studies have shown that CRP and HDL-C are closely related to the occurrence and development of cardiovascular diseases. Multiple studies have established risk prediction models for cardiovascular disease and found inflammation and cholesterol index as high risk factors for occurrence and development. Due to the inflammation and the lipid metabolism [6] correlation, the use of inflammatory-lipid indicators may predict the prognosis of cardiovascular disease, while a single inflammatory index or a single lipid index is susceptible to various confounders and is not independently and accurately predicted. Therefore, CRP/HDL-C is able to reflect the vascular damage caused by abnormal lipid metabolism, and both markers are inexpensive and simple to use in clinical practice. There are few reported studies on the association of CRP/HDL-C with MVA. Therefore, this study intends to evaluate the value of CRP/HDL-C in the diagnosis of MVA by measuring the CRP and HDL-C levels in the serum of MVA patients, in order to provide a reference for the early diagnosis of MVA and patients, which is reported below. 2. Data and methods 2.1 General information In this study, 70 patients diagnosed with MVA in the Department of Cardiovascular Medicine of the Second Affiliated Hospital of Dalian Medical University between September 2022 and December 2/2023 were selected as the observation group, Including 33 cases, female, and 37 male, The mean age was 58.78 ± 9.27 years old; At the same time, 68 patients with "chest pain" were selected, Patients with normal coronary angiography or stenosis < 50% and negative exercise plate test results were used as the control group, Including both 33 females and 35 males, The mean age was 60.62 ± 10.11 years; The study protocol was approved by the Ethics Committee of the Second Affiliated Hospital of Dalian Medical University. MVA diagnostic criteria: MVA diagnostic criteria established by the 2018 International Coronary Momotor Disorder Study Group (Coronary Vasomotion Disorders International Study Group, COVADIS) [7] : ① Myocardial ischemia symptoms such as angina pectoris, but no specific ischemia on ECG; ② coronary angiography showed normal coronary or stenosis < 50%; ③ positive exercise test or exercise plate test (ST level shift 0.1 mV during and after exercise for at least 2 minutes; typical angina symptoms during exercise; ST back elevation 0.1 mV, for more than 1 minute; blood pressure decreased by 10mmHg during exercise) [8] ; ④ Slow flow phenomenon in coronary arteries: at least one coronary artery corrected TIMI (Thrombolysis In Myocardial Infarction) flow frame number > 27 frames [9] 。 Inclusion criteria were: (1) patients with "chest pain" aged between 37 and 85 years; and (2) patients who were conscious and able to communicate normally.(3) Compliance with the MVA diagnosis. Exclusion criteria:①Previous acute myocardial infarction, revascularization such as coronary stent implantation and coronary bypass grafting; ② hypertensive heart disease, rheumatic heart disease, heart failure and other organic heart disease; ③ severe liver and kidney insufficiency; ④ non-cardiac chest pain caused by intercostal neuralgia, pleural disease; ⑤ uncontrolled or abnormal hemodynamics; ⑥ with active inflammation; ⑦ malignant tumor; ⑧ recent use of amiodarone, digoxin, propafenone and other drugs that affect test results. 2.2 Methods 2.2.1 Collect data and collect detailed clinical data of patients, including gender, age, physical constitution index (Body Mass Index BMI), history of diabetes, history of hypertension, smoking history, etc. Early morning fasting venous blood was collected for liver function, including albumin (ALB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), etc. Automatic biochemical instrument (Beckman) for high density lipoprotein cholesterol (HDL-C), C reactive protein (CRP), blood creatinine (sCr), and CRP/HDL-C was calculated. Left ventricular ejection fraction (Left ventricular ejection fraction LVEF) was measured in all patients using color Doppler ultrasound instruments. Blood collection was completed before the use of therapeutic myocardial ischemic drugs, such as antiplatelet aggregation drugs, nitrates, β -blockers, etc. 2.2.2 According to the results of coronary angiography, patients with no obvious abnormality or stenosis < 50% and exercise plate test or positive 12 leads (0.1 mv) were included in the observation group (n = 70), vascular stenosis was also less than 50% or no obvious abnormality, and negative exercise plate test or Holter test were included in the control group (n = 68). 2.3 Statistical Processing The data of this study were IBM SPSS 26.0 and Graphpad prism 9.5 and analyzed by statistical software.‾first, Use the Shapiro-Wilk test to determine whether the measurement data follows the normal distribution; Using x ± s representation for measurement data meeting a normal distribution, And perform the group t-test; For non-normally distributed measurements using M (Q1, Q3) representation, And performed a Manne-Whitney U test; The count data is expressed as [cases (%)], And perform a chi-square test; Multivariate Logistic regression method was also used for multivariate screening; at the same time, Mapping the Subject-subject operating characteristics (receiver operating characteristic, ROC) curve, Calculate the area under the curve (area under the curve, AUC) to assess the predictive value of CRP / HDL for MVA, And to determine the optimal cutoff value. The results were statistically significant when P 0.05). See Table 1 . 3.2 Comparison of laboratory data, the differences in AST, ALT, ALB, sCr, LDL-C, HDL-C, and LVEF were not significant (P > 0.05); however, the differences in CRP and CHR were significant (P < 0.001), in which the observation group had higher CRP and CHR than the control group. See Table 1 . 3.3 Comparison of serum CHR levels between the observation and control groups, the serum CHR in the observation group (13.59 ± 5.36) and the control group (11.15 ± 2.83), and these differences were statistically significant (P < 0.001). See Table 1 , Fig. 1 . Table 1 Comparison of clinical data and laboratory indicators between the two groups Clinical indicators Observation group (n = 70) Control group (n = 68) t/z/x2 P price Age (years, x ± s) 57.66 ± 10.02 60.62 ± 10.11 -1.727 0.086 Gender [example (%)] 37(52.9) 35(51.5) 0.027 0.871 Smoking [example (%)] 34(48.6) 24(35.3) 2.496 0.114 Hypertension [Case (%)] 37(52.9) 39(57.4) 0.282 0.596 Diabetes mellitus [for example, (%)] 17(24.3) 21(30.9) 0.752 0.386 BMI(x ± s) 25.16 ± 2.91 25.25 ± 2.96 -0.714 0.862 AST[U/L,M(Q1, Q3)] 22.56(16,28) 22.74(18,26) -0.781 0.435 ALT[U/L,M(Q1, Q3)] 23.89(15,26.25) 23.03(16,25.75) -0.200 0.841 Scr[mg/dl,M(Q1, Q3)] 67.36(55.32,77.97) 66.92(51.94,83.31) -0.635 0.526 LVEF[%,M(Q1, Q3)] 60(58,62) 60(61,59) -1.308 0.191 LDL-C[mmol/L, M(Q1, Q3)] 2.94(2.28,3.42) 2.75(2.24,3.23) -0.488 0.626 HDL-C[mmol/L, M(Q1, Q3)] 1.31(1.04,1.60) 1.22(1.11,1.32) -0.914 0.361 ALB(g/l,x ± s) 41.74 ± 3.13 42.18 ± 3.42 -0.765 0.446 CRP(mg/dl,x ± s) 5.13 ± 1.69 3.57 ± 0.87 6.733 < 0.001 CHR (x ± s) 4.17 ± 1.75 2.96 ± 0.85 -5.169 < 0.001 BMI: Body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase; Scr: serum creatinine; LVEF: left ventricular ejection fraction; LDL-C; LDL-C: high-density lipoprotein cholesterol; ALB: albumin; CRP: C-reactive protein; CHR: C-reactive protein / high-density lipoprotein cholesterol 3.4 Logistic regression analysis of MVA risk factors These statistically significant variables such as CRP and CHR were taken as independent variables, and whether MVA was taken as the dependent variable (assigned 0 = control group, 1 = MVA group, observation group) was included in the multivariate Logistic regression analysis. The results showed that CRP and CHR were independent risk factors for MVA, and the increased level of serum CHR increased the risk of MVA. See Table 2 . Table 2 Multivariate Logistic regression analysis of MVA risk factors variable β OR price 95%CI P price CRP 0.056 1.057 0.640 ~ 1.745 < 0.001 CHR 0.720 2.055 1.481 ~ 2.851 < 0.001 CRP: C-reactive protein; CHR: C-reactive protein / HDL cholesterol 3.5 Prediction analysis of serum CHR on MVA as a clinical indicator of predicting MVA, ROC, curve analysis showed that the area under the curve (AUC) of serum CHR was 0.724, the optimal cut-off value of 13.36, sensitivity of 45.7% and specificity of 85.3%. These results indicate that the serum CHR is able to more accurately predict the occurrence of MVA. See Table 3 , Fig. 2 . Table 3 Serum CAR, HCY / HDL-C and the combination predicted MVA Results of the ROC curve analysis variable The Cut Off value sensibility (%) specificity (%) AUC 95%CI CRP 5.05 52.9 98.5 0.771 0.693 ~ 0.849 CHR 13.36 65.7 85.3 0.724 0.638 ~ 0.810 CRP: C-reactive protein; CHR: C-reactive protein / HDL cholesterol 4. Discussion MVA is common in patients with cardiovascular risk factors and is associated with an elevated risk of adverse cardiovascular events, which is characterized by high morbidity, a low diagnostic rate and a low poor prognosis [10–12] 。Relevant studies have shown that [13] , In the myocardial ischemia population, the prevalence of MVA is about 40% – 64%, but only about 6.3% of the population has received timely diagnosis and treatment. While MVA is a special form of coronary heart disease, its diagnostic criteria [14] Is: symptoms of myocardial ischemia, reduced coronary flow reserve or microvasospasm, and recordable myocardial ischemia. In order to confirm MVA, patients need multiple coronary angiography, which is a heavy medical burden for the patient. The National Heart, Lung, and Blood Institute Research Study [2] It is considered that MVA patients have a poor prognosis, and that MVA is also a reliable and independent predictor of adverse cardiovascular events. Therefore, early screening and intervention for MVA appear particularly important. This study confirmed that CRP / HDL-C is an independent predictor of MVA diagnosis and can provide more possibilities for early diagnosis and early intervention treatment. CRP/HDL-C in the evaluation of coronary lesions will receive more attention. research finding [15] , MVA is the result of multifactorial, multiple mechanisms, including vascular endothelial dysfunction, inflammatory response, abnormal hemodynamics, and cardiac autonomic dysfunction are the causes of abnormal coronary microcirculation. Recent studies have shown that the [16] The impairment of vascular endothelial function is one of the main causes of coronary microcirculation diseases, in which inflammatory response plays a key role. Some inflammatory markers such as CRP can promote the activation and abnormal function of endothelial cells, and then lead to the occurrence of abnormal microcirculation function. Research proved that [17–18] C-reactive protein (CRP) has significant negative effects on various physiological processes, including activation of the complement system, damage to endothelial cells, inhibition of fibrinolysis, and participation in the uptake of LDL-C by macrophages, prompting conversion into foam cells. In addition, it adversely affects the vasomotor function of blood vessels and inducinflammatory reactions in vascular endothelial cells, which plays a key role in the development and development of coronary heart disease.research finding [19–20] CRP is a biomarker of inflammation, and elevated CRP is more likely associated with the occurrence of CAD. Binding of the CRP and the lipid markers [21–22] , Such as CRP and triglyceride-glucose binding, CRP and residual lipoprotein cholesterol index binding, have been used clinically as prognostic predictors of CHD. The interplay between lipid metabolism and inflammation is very important in the development and progression of cardiovascular diseases.research finding [23] The main effects of HDL-C in cardiovascular diseases are manifested in anti-inflammatory, anti-oxidation, vasodilation, anti-thrombosis, etc. HDL can mediate the clearance of lipid macrophage cholesterol by reversing cholesterol transport, and participate in the intermediate process of inhibiting atherosclerosis. Other studies have found that [24] The anti-inflammatory effect of HDL prevents oxidative modification of LDL, and HDL also reduces CRP, induced the expression of adhesion molecules on the surface of endothelial cells, thus conferring anti-inflammatory capability.research finding[25–26]HDL prevents T lymphocytes and monocytes from adhering to the vascular endothelium and migrate to atherosclerotic areas.by contraries [27] , Inflammation leads to the reduction of HDL and structural changes, and the related proteins and enzymes involved in HDL metabolism are significantly altered. There is a study[28]Believe that a negative interaction between abnormal blood lipid levels and CRP may reduce the cardiovascular risk. From a large cohort study showed that[29], High CRP /HDL-C ratio is an important risk factor for cardiovascular disease and cardiac problems, and early intervention in patients with elevated CRP/HDL-C ratio may further reduce the incidence of cardiovascular disease. This study found that the serum level of CRP /HDL-C (4.17 ± 1.7 ± 1.75 vs 2.172.96 ± 0.85, P < 0.001) was significantly higher in patients in the control group, with a statistically significant difference. Multivariate Logistic regression analysis showed that the serum CRP / HDL-C (OR = 2.055,95%CI: 1.481–2.851, P < 0.001) level was an independent risk factor for MVA. In addition, the ROC curve and AUC analysis showed that serum CRP / HDL-C could effectively predict MVA and provide good positive predictive value (AUC = 0.724), with sensitivity of 65.7% and specificity of 85.3%. 5. Conclusion In conclusion, CRP/HDL-C may have a key role in the occurrence and development of MVA.yet, There are still some limitations to this study: First, This study is a single-center case-control study, All study subjects were from patients attending the same hospital during the same period, There may be a selection bias; next, The small sample size, Limited geographical scope, Limiting the persuasion of the study conclusions, Therefore, further multi-center and large-sample studies are needed to provide more sufficient evidence; besides, The data for CRP and HDL-C were obtained from single blood sample tests before coronary angiography, Dynamic detection has not been continuously, Whether the CRP/HDL-C will change after coronary angiography deserves further attention and investigation. Overall, CRP/ HDL-C reflects the inflammatory reaction and abnormal lipid metabolism, respectively, enabling better prediction of microvascular angina, which may be a potential, easily measured and affordable parameter for the diagnosis of MVA. Declarations Author Contribution wxz wrote the main manuscript text and prepared figures 1-3. lw ,yxc and xfz reviewed the manuscript References Kurl S, Jae SY, Voutilainen A,et al.The combined effect of blood pressure and C-reactive protein with the risk of mortality from coronary heart and cardiovascular diseases[J].Nutr Metab Cardiovasc Dis,2021 31(7):2051-2057. Del Buono MG, Montone RA, Camilli M, et al.Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases:JACC State-of-the-Art Review[J].Am Coll Cardiol,2021 78 (13) :1352-1371. Marios Sagris ,Panagiotis Theofilis ,Alexios S Antonopoulos ,et al.Inflammation in Coronary Microvascular Dysfunction[J].Int J Mol Sci,2021,22（24）:13471. Kurl S, Jae SY, Voutilainen A, et al.The combined effect of blood pressure and C-reactive protein with the risk of mortality from coronary heart and cardiovascular diseases［J］.Nutr Metab Cardiovasc Dis, 2021, 31(7): 2051-2057. Zhong Jiankai, Tan Ying, Chen Yingwen, etc. Effect of homocysteine on HDL retrotransport and antioxidant function [J]. Chinese Journal of Elderly Cardiovascular and cerebrovascular Diseases, 2016,18 (3): 233-236. Cetin MS, Ozcan Cetin EH, Kalender E, Aydin S, Topaloglu S, Kisacik HL, Tem izhan A.Monocyte to HDL cholesterol ratio predicts coronary artery Disease Severity and Future Major Cardiovascular adverse events in Acute Coronary Syndrome.Heart Lung Circ, 2016，25(11), 1077–86. https://doi.org/10.1016/j.hlc.2016.02.023. Ong P, Camici PG, Beltrame JF, Crea F, Shimokawa H, Sechtem U, Kaski J C, Bairey Merz C N.International standardization of diagnostic criteria for microvascular angina[J].International Journal of Cardiology, 2018,250:16-20. Ma Guochao, Lin Chuanghui. Efficacy of extracorporeal stroke in patients with positive ECG exercise plate test [J]. Heilongjiang Medicine, 2020,33 (5): 1160-1162. Konrad Stępień , Karol Nowak, Aleksandra Karcińska.,et al.Coronary Slow-Flow Phenomenon in Takotsubo Syndrome: The Prevalence, Clinical Determinants, and Long-Term Prognostic Impact[J].Int J Mol Sci, 2024,25(2):1297. Bradley C, Berry C.De fi nition and epidemiology of coronary microvascular disease [J].Nucl Cardiol ,2022, 29:1763–75. Sucato V, Madaudo C, Galassi AR.Classi fi cation, diagnosis, and treatment of coronary microvascular dysfunction [J].Clin Med ,2022,11(15):4610. Schindler TH, Dilsizian V.Coronary microvascular dysfunction: clinical considerations and noninvasive diagnosis [J].ACC Cardiovasc Imaging ,2020,13:140–55. Chen C, Wei J, AlBadri A, Zarrini P, Bairey MC.Coronary microvascular d ysfunction epidemiology, pathogenesis, prognosis, diagnosis, risk factors and therapy [J].Circ J ,2016,81:3–11. Diagnostic criteria for coronary artery microangiopathy [J]. Clinical Journal of Traditional Chinese Medicine, 2023,35 (5): 1046-1047. Hu Gl. Progress in coronary microcirculatory disorders [J]. Journal of microcirculation, 2013,23 (4): 60-65. Marija Zdravkovic, Viseslav Popadic , Slobodan Klasnja,et al .Coronary Microvascular Dysfunction and Hypertension: A Bond More Important than We Think[J].Medicina (Kaunas),2023,59(12):2149. Chen YL , Marc D Cook ,Heather Grimm,et al.The Effect of Race and Shear Stresson CRP Induced Responses in Endothelial Cells[J]. Mediators Inflamm,2021,11(2):11-18. Caroline Dix, Johannes Zeller, Hannah Stevens,et al.C-reactive protein, immunothrombosis and venous thromboembolism[J].Review Front Immunol,2022, 13:1002652. Pau Llàcer , François Croset, Rafael de la Espriella,et al.Trajectory of Urine Albumin-Creatinine Ratio in Patients with Acute Heart Failure[J].Cardiorenal Med,2024,14(1):74-80. Linden MD, Jackson DE.Platelets: pleiotropic roles in atherogenesis and atherothrombosis[J].Int J Biochem Cell Biol,2010 ,42(11):1762-1766. Xia MY, Xu TL, Ni RZ,et al. Correlation analysis of C reactive protein to albumin ratio and neutrophil to lymphocyte ratio with coronary artery lesions in postmenopausal women [J]. The Chinese Cardiovascular Disease Study, 2023,21 (5): 390-396. Khattab MH, Shahwan MJ, Hassan NAGM, Jairoun AA.Abnormal high-sensitivity C-reactive protein is Associated with an increased risk of Cardiovascular Disease and Renal Dysfunction among patients diagnosed with type 2 diabetes Mellitus in Palestine[J].Rev Diabet Stud.2022;18(1):27–33. Yao SM, Zheng PP, Wan YH, Dong W, Miao GB, Wang H, Yang JF.Adding highsensitivity C-reactive protein to frailty assessment to predict mortality and cardiovascular events in elderly inpatients with cardiovascular disease[J].Exp Gerontol.2021;146:111235. Feng G, Yang M, Xu L, Liu Y, Yu J, Zang Y, Shen S, Zheng X.Combined effects of high sensitivity C-reactive protein and triglyceride-glucose index on risk of cardiovascular disease among middle-aged and older Chinese: evidence from the China Health and Retirement Longitudinal Study, Nutr.[J].MetaCardiovasc Dis.2023;33(6):1245–53. .Chevli PA, Islam T, Pokharel Y, Rodriguez F, Virani SS, Blaha MJ, Bertoni AG, Budoff M, Otvos JD, Shapiro MD.Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the multi-ethnic study of atherosclerosis (MESA) [J].J Clin Lipidol.2022;16(6):870–7. .Kosmas CE, Martinez I, Sourlas A, Bouza KV, Campos FN, Torres V, Montan PD, Guzman E.High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease[J].Drugs Context.2018;7:212525. Lampka M, Olszewska-Słonina D, Hołyńska-Iwan I, Grąbczewska Z, Obońska K, Cwynar A, Stępowska J, Szewczyk-Golec K.Effect of low high-density lipopro tein level on endothelial activation and prothrombotic processes in coronary artery Disease-A Pilot Study[J].Int J Environ Res Public Health.2022;19(14):8637. Constans J, Conri C.Circulating markers of endothelial function in cardiovascular disease [J].Clin Chim Acta.2006;368(1-2):33-47. Tretjakovs P, Lurins J, Svirskis S, Gersone G, Lurina D, Rozenberga U, Blumfelds L, Bahs G, Lejnieks A, Mackevics V. Thioredoxin-1 and Correlations of the Plasma Cytokines Regarding Aortic Valve Stenosis Severity[J]. Biomedicines. 2021 ,9(8):1041. Verbovenko J, Bahs G.Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina[J].Clin Chim Acta ,2012,413(1-2):2529. Feingold KR, Grunfeld C et al.The Effect of Inflammation and Infection on Lipids and Lipoproteins.In: Feingold KR, Anawalt B, Blackman MR, eds.Endotext[J].South Dartmouth (MA): MDText.com, Inc.; March 7, 2022. Bafei SEC, Zhao X, Chen C, etal.Sun JInteractive effect of increased high sensitive C-reactive protein and dyslipidemia on cardiovascular diseases: a 12-year prospective cohort study [J].Lipids Health Dis.2023 ,22(1):113. Gao Y, Wang M, Wang R, Jiang J, Hu Y, Wang W, Wang Y, Li H (2024) The predictive value of the hs-CRP/HDL-C ratio, an inflammation-lipid composite marker, for cardiovascular disease in middle-aged and elderly people: evidence from a large national cohort study [J].Lipids Health Dis 2024,23(1):66 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4973475","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":357032602,"identity":"ac22bf6d-20e8-4057-87bd-9281a8b767d1","order_by":0,"name":"Wenxin Zhao","email":"","orcid":"","institution":"The Second Affiliated Hospital of Dalian MedicaI University","correspondingAuthor":false,"prefix":"","firstName":"Wenxin","middleName":"","lastName":"Zhao","suffix":""},{"id":357032603,"identity":"f7fa0b7c-6a4c-4004-ad43-4b8744dd18c8","order_by":1,"name":"Lida Wang","email":"","orcid":"","institution":"The Second Affiliated Hospital of Dalian MedicaI University","correspondingAuthor":false,"prefix":"","firstName":"Lida","middleName":"","lastName":"Wang","suffix":""},{"id":357032604,"identity":"20f1211e-c30c-4825-b6e5-34f452f55858","order_by":2,"name":"Yongxu Cai","email":"","orcid":"","institution":"The Second Affiliated Hospital of Dalian MedicaI University","correspondingAuthor":false,"prefix":"","firstName":"Yongxu","middleName":"","lastName":"Cai","suffix":""},{"id":357032606,"identity":"72eb6fdc-cc3c-4f17-a897-7438f912d250","order_by":3,"name":"Xianfeng Zhao","email":"","orcid":"","institution":"Fuwai Central China Cardiovascular Hospital","correspondingAuthor":false,"prefix":"","firstName":"Xianfeng","middleName":"","lastName":"Zhao","suffix":""},{"id":357032609,"identity":"e8ef170b-75c5-4940-b21d-d8019bf71f23","order_by":4,"name":"Zhongyan Li","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAwElEQVRIiWNgGAWjYBACfmb2gw8+VPyTsz/eQKQWyfaeZMMZZw4YM5w5QKQWgzMHzKR5Ww4kNtxIIFbLjYRkw5kNd4wZZz7eeIOhxiaasMNuJB588HHHMzlm6bRiC4ZjabkNhLTwgW05w2zMJp1jJsHYcJiwFoYbCUC/tDEn9kieIVKLANj7bYcTZ0jwEKkFGshpxgY8QL8kEOMXaFTayBmwH95440ONDRF+QQIGEgmkKIdoIVXHKBgFo2AUjAwAACm1RtszU/uuAAAAAElFTkSuQmCC","orcid":"","institution":"The Second Affiliated Hospital of Dalian MedicaI University","correspondingAuthor":true,"prefix":"","firstName":"Zhongyan","middleName":"","lastName":"Li","suffix":""}],"badges":[],"createdAt":"2024-08-25 15:52:52","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4973475/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4973475/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":66859797,"identity":"ff98225c-4aa7-4669-b7fc-87a73040ca9b","added_by":"auto","created_at":"2024-10-17 08:13:08","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":21193,"visible":true,"origin":"","legend":"\u003cp\u003eComparison of CHR levels between the control and MVA groups\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-4973475/v1/2a6a63802fd5fbfb0b302a56.png"},{"id":66859796,"identity":"5a7afe86-d598-4947-92d7-5fbfdd0eaadb","added_by":"auto","created_at":"2024-10-17 08:13:08","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":25854,"visible":true,"origin":"","legend":"\u003cp\u003eROC curves of serum CHR in patients with microvascular angina\u003c/p\u003e","description":"","filename":"floatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-4973475/v1/e22094b361ee2514e7066f01.png"},{"id":100481384,"identity":"61d3e8bf-8170-4860-af08-4bd46fa7a4be","added_by":"auto","created_at":"2026-01-17 14:39:28","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":507845,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4973475/v1/f66b6cbe-f6a3-462e-9c77-2b842e96cd2d.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"The diagnostic value of serum C-reactive protein/high-density lipoprotein in microvascular angina","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eMicrovascular angina pectoris (microvascular angina, MVA) is a clinical syndrome\u003csup\u003e[1]\u003c/sup\u003e, Which is characterized by structural and functional abnormalities of anterior coronary arterioles, arterioles and capillaries. It is precisely because of these abnormalities in microvascular structure and function that MVA patients are at a significantly increased risk of major cardiovascular adverse events such as heart failure and acute coronary syndrome, so timely identification and intervention of MVA patients is crucial. At present, common methods for MVA diagnosis include invasive methods such as coronary angiography, intra-coronary Doppler blood flow guide wire, noninvasive methods such as cardiac magnetic resonance imaging, positron emission computed tomography imaging and single-photon emission computed tomography imaging\u003csup\u003e[2]\u003c/sup\u003e, But these inspection techniques are difficult to popularize, mainly because of their high cost and high technical requirements. Therefore, it is urgent to develop a simple, non-invasive and reliable serological diagnostic method. According to studies, the pathogenesis of MVA is closely related to the inflammatory response and dysfunction of coronary microvessels\u003csup\u003e[3]\u003c/sup\u003e。C-reactive protein (C-reactive protein, CRP) is an acute time-phase inflammatory marker, and its level is positively correlated with the inflammatory status of the body, which can reflect the diagnosis and prognosis of coronary heart disease (coronary heart disease, CHD) to some extent\u003csup\u003e[4]\u003c/sup\u003e. High-density lipoprotein cholesterol (HDL-C) not only participates in cholesterol reverse, but also slows the progression of atherosclerosis through antioxidant, anti-inflammatory and improvement of endothelial cell function\u003csup\u003e[5]\u003c/sup\u003e. Studies have shown that CRP and HDL-C are closely related to the occurrence and development of cardiovascular diseases. Multiple studies have established risk prediction models for cardiovascular disease and found inflammation and cholesterol index as high risk factors for occurrence and development. Due to the inflammation and the lipid metabolism\u003csup\u003e[6]\u003c/sup\u003ecorrelation, the use of inflammatory-lipid indicators may predict the prognosis of cardiovascular disease, while a single inflammatory index or a single lipid index is susceptible to various confounders and is not independently and accurately predicted. Therefore, CRP/HDL-C is able to reflect the vascular damage caused by abnormal lipid metabolism, and both markers are inexpensive and simple to use in clinical practice. There are few reported studies on the association of CRP/HDL-C with MVA. Therefore, this study intends to evaluate the value of CRP/HDL-C in the diagnosis of MVA by measuring the CRP and HDL-C levels in the serum of MVA patients, in order to provide a reference for the early diagnosis of MVA and patients, which is reported below.\u003c/p\u003e"},{"header":"2. Data and methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\n \u003ch2\u003e2.1 General information\u003c/h2\u003e\n \u003cp\u003eIn this study, 70 patients diagnosed with MVA in the Department of Cardiovascular Medicine of the Second Affiliated Hospital of Dalian Medical University between September 2022 and December 2/2023 were selected as the observation group, Including 33 cases, female, and 37 male, The mean age was 58.78\u0026thinsp;\u0026plusmn;\u0026thinsp;9.27 years old; At the same time, 68 patients with \u0026quot;chest pain\u0026quot; were selected, Patients with normal coronary angiography or stenosis\u0026thinsp;\u0026lt;\u0026thinsp;50% and negative exercise plate test results were used as the control group, Including both 33 females and 35 males, The mean age was 60.62\u0026thinsp;\u0026plusmn;\u0026thinsp;10.11 years; The study protocol was approved by the Ethics Committee of the Second Affiliated Hospital of Dalian Medical University.\u003c/p\u003e\n \u003cp\u003eMVA diagnostic criteria: MVA diagnostic criteria established by the 2018 International Coronary Momotor Disorder Study Group (Coronary Vasomotion Disorders International Study Group, COVADIS)\u003csup\u003e[7]\u003c/sup\u003e: ① Myocardial ischemia symptoms such as angina pectoris, but no specific ischemia on ECG; ② coronary angiography showed normal coronary or stenosis\u0026thinsp;\u0026lt;\u0026thinsp;50%; ③ positive exercise test or exercise plate test (ST level shift 0.1 mV during and after exercise for at least 2 minutes; typical angina symptoms during exercise; ST back elevation 0.1 mV, for more than 1 minute; blood pressure decreased by 10mmHg during exercise)\u003csup\u003e[8]\u003c/sup\u003e; ④ Slow flow phenomenon in coronary arteries: at least one coronary artery corrected TIMI (Thrombolysis In Myocardial Infarction) flow frame number\u0026thinsp;\u0026gt;\u0026thinsp;27 frames\u003csup\u003e[9]\u003c/sup\u003e。\u003c/p\u003e\n \u003cp\u003eInclusion criteria were: (1) patients with \u0026quot;chest pain\u0026quot; aged between 37 and 85 years; and (2) patients who were conscious and able to communicate normally.(3) Compliance with the MVA diagnosis.\u003c/p\u003e\n \u003cp\u003eExclusion criteria:①Previous acute myocardial infarction, revascularization such as coronary stent implantation and coronary bypass grafting; ② hypertensive heart disease, rheumatic heart disease, heart failure and other organic heart disease; ③ severe liver and kidney insufficiency; ④ non-cardiac chest pain caused by intercostal neuralgia, pleural disease; ⑤ uncontrolled or abnormal hemodynamics; ⑥ with active inflammation; ⑦ malignant tumor; ⑧ recent use of amiodarone, digoxin, propafenone and other drugs that affect test results.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e\n \u003ch2\u003e2.2 Methods\u003c/h2\u003e2.2.1 Collect data and collect detailed clinical data of patients, including gender, age, physical constitution index (Body Mass Index BMI), history of diabetes, history of hypertension, smoking history, etc. Early morning fasting venous blood was collected for liver function, including albumin (ALB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), etc. Automatic biochemical instrument (Beckman) for high density lipoprotein cholesterol (HDL-C), C reactive protein (CRP), blood creatinine (sCr), and CRP/HDL-C was calculated. Left ventricular ejection fraction (Left ventricular ejection fraction LVEF) was measured in all patients using color Doppler ultrasound instruments. Blood collection was completed before the use of therapeutic myocardial ischemic drugs, such as antiplatelet aggregation drugs, nitrates, \u0026beta; -blockers, etc.\n\u003c/div\u003e\n\u003cp\u003e2.2.2 According to the results of coronary angiography, patients with no obvious abnormality or stenosis\u0026thinsp;\u0026lt;\u0026thinsp;50% and exercise plate test or positive 12 leads (0.1 mv) were included in the observation group (n\u0026thinsp;=\u0026thinsp;70), vascular stenosis was also less than 50% or no obvious abnormality, and negative exercise plate test or Holter test were included in the control group (n\u0026thinsp;=\u0026thinsp;68).\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003e2.3 Statistical Processing The data of this study were IBM SPSS 26.0 and Graphpad prism 9.5 and analyzed by statistical software.\u0026oline;first, Use the Shapiro-Wilk test to determine whether the measurement data follows the normal distribution; Using x\u0026thinsp;\u0026plusmn;\u0026thinsp;s representation for measurement data meeting a normal distribution, And perform the group t-test; For non-normally distributed measurements using M (Q1, Q3) representation, And performed a Manne-Whitney U test; The count data is expressed as [cases (%)], And perform a chi-square test; Multivariate Logistic regression method was also used for multivariate screening; at the same time, Mapping the Subject-subject operating characteristics (receiver operating characteristic, ROC) curve, Calculate the area under the curve (area under the curve, AUC) to assess the predictive value of CRP / HDL for MVA, And to determine the optimal cutoff value. The results were statistically significant when P\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003cbr\u003e\u003c/span\u003e\u003c/p\u003e"},{"header":"3 Results","content":"\u003cp\u003e3.1 General Data The differences between the observation and control groups in age, sex, BMI, history of hypertension, smoking and diabetes (P\u0026thinsp;\u0026gt;\u0026thinsp;0.05). See Table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e\n\u003cp\u003e3.2 Comparison of laboratory data, the differences in AST, ALT, ALB, sCr, LDL-C, HDL-C, and LVEF were not significant (P\u0026thinsp;\u0026gt;\u0026thinsp;0.05); however, the differences in CRP and CHR were significant (P\u0026thinsp;\u0026lt;\u0026thinsp;0.001), in which the observation group had higher CRP and CHR than the control group. See Table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003e3.3 Comparison of serum CHR levels between the observation and control groups, the serum CHR in the observation group (13.59\u0026thinsp;\u0026plusmn;\u0026thinsp;5.36) and the control group (11.15\u0026thinsp;\u0026plusmn;\u0026thinsp;2.83), and these differences were statistically significant (P\u0026thinsp;\u0026lt;\u0026thinsp;0.001). See Table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e, Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/span\u003e\u0026nbsp;\u003c/p\u003e\u0026nbsp;\u003ctable id=\"Tab1\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\n \u003cdiv class=\"CaptionContent\"\u003e\n \u003cp\u003eComparison of clinical data and laboratory indicators between the two groups\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003eClinical indicators\u003cbr\u003e\u003c/th\u003e\n \u003cth align=\"left\"\u003eObservation group (n\u0026thinsp;=\u0026thinsp;70)\u003cbr\u003e\u003c/th\u003e\n \u003cth align=\"left\"\u003eControl group (n\u0026thinsp;=\u0026thinsp;68)\u003cbr\u003e\u003c/th\u003e\n \u003cth align=\"left\"\u003et/z/x2\u003cbr\u003e\u003c/th\u003e\n \u003cth align=\"left\"\u003eP price\u003cbr\u003e\u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eAge (years, x\u0026thinsp;\u0026plusmn;\u0026thinsp;s)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e57.66\u0026thinsp;\u0026plusmn;\u0026thinsp;10.02\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e60.62\u0026thinsp;\u0026plusmn;\u0026thinsp;10.11\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e-1.727\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.086\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eGender [example (%)]\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e37(52.9)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e35(51.5)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.027\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.871\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eSmoking [example (%)]\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e34(48.6)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e24(35.3)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e2.496\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.114\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eHypertension [Case (%)]\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e37(52.9)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e39(57.4)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.282\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.596\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eDiabetes mellitus [for example, (%)]\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e17(24.3)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e21(30.9)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.752\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.386\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eBMI(x\u0026thinsp;\u0026plusmn;\u0026thinsp;s)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e25.16\u0026thinsp;\u0026plusmn;\u0026thinsp;2.91\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e25.25\u0026thinsp;\u0026plusmn;\u0026thinsp;2.96\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e-0.714\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.862\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eAST[U/L,M(Q1, Q3)]\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e22.56(16,28)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e22.74(18,26)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e-0.781\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.435\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eALT[U/L,M(Q1, Q3)]\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e23.89(15,26.25)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e23.03(16,25.75)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e-0.200\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.841\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eScr[mg/dl,M(Q1, Q3)]\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e67.36(55.32,77.97)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e66.92(51.94,83.31)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e-0.635\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.526\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eLVEF[%,M(Q1, Q3)]\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e60(58,62)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e60(61,59)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e-1.308\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.191\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eLDL-C[mmol/L, M(Q1, Q3)]\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e2.94(2.28,3.42)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e2.75(2.24,3.23)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e-0.488\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.626\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eHDL-C[mmol/L,\u003cbr\u003eM(Q1, Q3)]\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e1.31(1.04,1.60)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e1.22(1.11,1.32)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e-0.914\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.361\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eALB(g/l,x\u0026thinsp;\u0026plusmn;\u0026thinsp;s)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e41.74\u0026thinsp;\u0026plusmn;\u0026thinsp;3.13\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e42.18\u0026thinsp;\u0026plusmn;\u0026thinsp;3.42\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e-0.765\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.446\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eCRP(mg/dl,x\u0026thinsp;\u0026plusmn;\u0026thinsp;s)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e5.13\u0026thinsp;\u0026plusmn;\u0026thinsp;1.69\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e3.57\u0026thinsp;\u0026plusmn;\u0026thinsp;0.87\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e6.733\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e\u0026lt;\u0026thinsp;0.001\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eCHR (x\u0026thinsp;\u0026plusmn;\u0026thinsp;s)\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e4.17\u0026thinsp;\u0026plusmn;\u0026thinsp;1.75\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"left\"\u003e2.96\u0026thinsp;\u0026plusmn;\u0026thinsp;0.85\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e-5.169\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e\u0026lt;\u0026thinsp;0.001\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003ctfoot\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"5\"\u003eBMI: Body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase; Scr: serum creatinine; LVEF: left ventricular ejection fraction; LDL-C; LDL-C: high-density lipoprotein cholesterol; ALB: albumin; CRP: C-reactive protein; CHR: C-reactive protein / high-density lipoprotein cholesterol\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tfoot\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003c/p\u003e\n\u003cp\u003e3.4 Logistic regression analysis of MVA risk factors These statistically significant variables such as CRP and CHR were taken as independent variables, and whether MVA was taken as the dependent variable (assigned 0\u0026thinsp;=\u0026thinsp;control group, 1\u0026thinsp;=\u0026thinsp;MVA group, observation group) was included in the multivariate Logistic regression analysis. The results showed that CRP and CHR were independent risk factors for MVA, and the increased level of serum CHR increased the risk of MVA. See Table \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e.\u0026nbsp;\u003c/p\u003e\u0026nbsp;\u003ctable id=\"Tab2\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\n \u003cdiv class=\"CaptionContent\"\u003e\n \u003cp\u003eMultivariate Logistic regression analysis of MVA risk factors\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003evariable\u003cbr\u003e\u003c/th\u003e\n \u003cth align=\"left\"\u003e\u0026beta;\u003cbr\u003e\u003c/th\u003e\n \u003cth align=\"left\"\u003eOR price\u003cbr\u003e\u003c/th\u003e\n \u003cth align=\"left\"\u003e95%CI\u003cbr\u003e\u003c/th\u003e\n \u003cth align=\"left\"\u003eP price\u003cbr\u003e\u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eCRP\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.056\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e1.057\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.640\u0026thinsp;~\u0026thinsp;1.745\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e\u0026lt;\u0026thinsp;0.001\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eCHR\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.720\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e2.055\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e1.481\u0026thinsp;~\u0026thinsp;2.851\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e\u0026lt;\u0026thinsp;0.001\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003ctfoot\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"5\"\u003eCRP: C-reactive protein; CHR: C-reactive protein / HDL cholesterol\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tfoot\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003c/p\u003e\n\u003cp\u003e3.5 Prediction analysis of serum CHR on MVA as a clinical indicator of predicting MVA, ROC, curve analysis showed that the area under the curve (AUC) of serum CHR was 0.724, the optimal cut-off value of 13.36, sensitivity of 45.7% and specificity of 85.3%. These results indicate that the serum CHR is able to more accurately predict the occurrence of MVA. See Table \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e, Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e.\u0026nbsp;\u003c/p\u003e\u0026nbsp;\u003ctable id=\"Tab3\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e\n \u003cdiv class=\"CaptionContent\"\u003e\n \u003cp\u003eSerum CAR, HCY / HDL-C and the combination predicted MVA Results of the ROC curve analysis\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003evariable\u003cbr\u003e\u003c/th\u003e\n \u003cth align=\"left\"\u003eThe Cut Off value\u003cbr\u003e\u003c/th\u003e\n \u003cth align=\"left\"\u003esensibility (%)\u003cbr\u003e\u003c/th\u003e\n \u003cth align=\"left\"\u003especificity (%)\u003cbr\u003e\u003c/th\u003e\n \u003cth align=\"left\"\u003eAUC\u003cbr\u003e\u003c/th\u003e\n \u003cth align=\"left\"\u003e95%CI\u003cbr\u003e\u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eCRP\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e5.05\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e52.9\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e98.5\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.771\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.693\u0026thinsp;~\u0026thinsp;0.849\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003eCHR\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e13.36\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e65.7\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e85.3\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.724\u003cbr\u003e\u003c/td\u003e\n \u003ctd align=\"char\"\u003e0.638\u0026thinsp;~\u0026thinsp;0.810\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003ctfoot\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"6\"\u003eCRP: C-reactive protein; CHR: C-reactive protein / HDL cholesterol\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tfoot\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003c/p\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eMVA is common in patients with cardiovascular risk factors and is associated with an elevated risk of adverse cardiovascular events, which is characterized by high morbidity, a low diagnostic rate and a low poor prognosis\u003csup\u003e[10\u0026ndash;12]\u003c/sup\u003e。Relevant studies have shown that\u003csup\u003e[13]\u003c/sup\u003e, In the myocardial ischemia population, the prevalence of MVA is about 40% \u0026ndash; 64%, but only about 6.3% of the population has received timely diagnosis and treatment. While MVA is a special form of coronary heart disease, its diagnostic criteria\u003csup\u003e[14]\u003c/sup\u003eIs: symptoms of myocardial ischemia, reduced coronary flow reserve or microvasospasm, and recordable myocardial ischemia. In order to confirm MVA, patients need multiple coronary angiography, which is a heavy medical burden for the patient. The National Heart, Lung, and Blood Institute Research Study\u003csup\u003e[2]\u003c/sup\u003eIt is considered that MVA patients have a poor prognosis, and that MVA is also a reliable and independent predictor of adverse cardiovascular events. Therefore, early screening and intervention for MVA appear particularly important. This study confirmed that CRP / HDL-C is an independent predictor of MVA diagnosis and can provide more possibilities for early diagnosis and early intervention treatment. CRP/HDL-C in the evaluation of coronary lesions will receive more attention.\u003c/p\u003e \u003cp\u003eresearch finding\u003csup\u003e[15]\u003c/sup\u003e, MVA is the result of multifactorial, multiple mechanisms, including vascular endothelial dysfunction, inflammatory response, abnormal hemodynamics, and cardiac autonomic dysfunction are the causes of abnormal coronary microcirculation. Recent studies have shown that the\u003csup\u003e[16]\u003c/sup\u003eThe impairment of vascular endothelial function is one of the main causes of coronary microcirculation diseases, in which inflammatory response plays a key role. Some inflammatory markers such as CRP can promote the activation and abnormal function of endothelial cells, and then lead to the occurrence of abnormal microcirculation function. Research proved that\u003csup\u003e[17\u0026ndash;18]\u003c/sup\u003eC-reactive protein (CRP) has significant negative effects on various physiological processes, including activation of the complement system, damage to endothelial cells, inhibition of fibrinolysis, and participation in the uptake of LDL-C by macrophages, prompting conversion into foam cells. In addition, it adversely affects the vasomotor function of blood vessels and inducinflammatory reactions in vascular endothelial cells, which plays a key role in the development and development of coronary heart disease.research finding\u003csup\u003e[19\u0026ndash;20]\u003c/sup\u003eCRP is a biomarker of inflammation, and elevated CRP is more likely associated with the occurrence of CAD. Binding of the CRP and the lipid markers\u003csup\u003e[21\u0026ndash;22]\u003c/sup\u003e, Such as CRP and triglyceride-glucose binding, CRP and residual lipoprotein cholesterol index binding, have been used clinically as prognostic predictors of CHD.\u003c/p\u003e \u003cp\u003eThe interplay between lipid metabolism and inflammation is very important in the development and progression of cardiovascular diseases.research finding\u003csup\u003e[23]\u003c/sup\u003eThe main effects of HDL-C in cardiovascular diseases are manifested in anti-inflammatory, anti-oxidation, vasodilation, anti-thrombosis, etc. HDL can mediate the clearance of lipid macrophage cholesterol by reversing cholesterol transport, and participate in the intermediate process of inhibiting atherosclerosis. Other studies have found that\u003csup\u003e[24]\u003c/sup\u003eThe anti-inflammatory effect of HDL prevents oxidative modification of LDL, and HDL also reduces CRP, induced the expression of adhesion molecules on the surface of endothelial cells, thus conferring anti-inflammatory capability.research finding[25\u0026ndash;26]HDL prevents T lymphocytes and monocytes from adhering to the vascular endothelium and migrate to atherosclerotic areas.by contraries\u003csup\u003e[27]\u003c/sup\u003e, Inflammation leads to the reduction of HDL and structural changes, and the related proteins and enzymes involved in HDL metabolism are significantly altered. There is a study[28]Believe that a negative interaction between abnormal blood lipid levels and CRP may reduce the cardiovascular risk. From a large cohort study showed that[29], High CRP /HDL-C ratio is an important risk factor for cardiovascular disease and cardiac problems, and early intervention in patients with elevated CRP/HDL-C ratio may further reduce the incidence of cardiovascular disease.\u003c/p\u003e \u003cp\u003eThis study found that the serum level of CRP /HDL-C (4.17\u0026thinsp;\u0026plusmn;\u0026thinsp;1.7\u0026thinsp;\u0026plusmn;\u0026thinsp;1.75 vs 2.172.96\u0026thinsp;\u0026plusmn;\u0026thinsp;0.85, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001) was significantly higher in patients in the control group, with a statistically significant difference. Multivariate Logistic regression analysis showed that the serum CRP / HDL-C (OR\u0026thinsp;=\u0026thinsp;2.055,95%CI: 1.481\u0026ndash;2.851, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001) level was an independent risk factor for MVA. In addition, the ROC curve and AUC analysis showed that serum CRP / HDL-C could effectively predict MVA and provide good positive predictive value (AUC\u0026thinsp;=\u0026thinsp;0.724), with sensitivity of 65.7% and specificity of 85.3%.\u003c/p\u003e"},{"header":"5. Conclusion","content":"\u003cp\u003eIn conclusion, CRP/HDL-C may have a key role in the occurrence and development of MVA.yet, There are still some limitations to this study: First, This study is a single-center case-control study, All study subjects were from patients attending the same hospital during the same period, There may be a selection bias; next, The small sample size, Limited geographical scope, Limiting the persuasion of the study conclusions, Therefore, further multi-center and large-sample studies are needed to provide more sufficient evidence; besides, The data for CRP and HDL-C were obtained from single blood sample tests before coronary angiography, Dynamic detection has not been continuously, Whether the CRP/HDL-C will change after coronary angiography deserves further attention and investigation.\u003c/p\u003e \u003cp\u003eOverall, CRP/ HDL-C reflects the inflammatory reaction and abnormal lipid metabolism, respectively, enabling better prediction of microvascular angina, which may be a potential, easily measured and affordable parameter for the diagnosis of MVA.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003ewxz wrote the main manuscript text and prepared figures 1-3. lw ,yxc and xfz reviewed the manuscript\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eKurl S, Jae SY, Voutilainen A,et al.The combined effect of blood pressure and C-reactive protein with the risk of mortality from coronary heart and cardiovascular diseases[J].Nutr Metab Cardiovasc Dis,2021 31(7):2051-2057.\u003c/li\u003e\n\u003cli\u003eDel Buono MG, Montone RA, Camilli M, et al.Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases:JACC State-of-the-Art Review[J].Am Coll Cardiol,2021 78 (13) :1352-1371.\u003c/li\u003e\n\u003cli\u003eMarios Sagris ,Panagiotis Theofilis ,Alexios S Antonopoulos ,et al.Inflammation in Coronary Microvascular Dysfunction[J].Int J Mol Sci,2021,22（24）:13471.\u003c/li\u003e\n\u003cli\u003eKurl S, Jae SY, Voutilainen A, et al.The combined effect of blood pressure and C-reactive protein with the risk of mortality from coronary heart and cardiovascular diseases［J］.Nutr Metab Cardiovasc Dis, 2021, 31(7): 2051-2057.\u003c/li\u003e\n\u003cli\u003eZhong Jiankai, Tan Ying, Chen Yingwen, etc. Effect of homocysteine on HDL retrotransport and antioxidant function [J]. Chinese Journal of Elderly Cardiovascular and cerebrovascular Diseases, 2016,18 (3): 233-236.\u003c/li\u003e\n\u003cli\u003eCetin MS, Ozcan Cetin EH, Kalender E, Aydin S, Topaloglu S, Kisacik HL, Tem izhan A.Monocyte to HDL cholesterol ratio predicts coronary artery Disease Severity and Future Major Cardiovascular adverse events in Acute Coronary Syndrome.Heart Lung Circ, 2016，25(11), 1077\u0026ndash;86. https://doi.org/10.1016/j.hlc.2016.02.023.\u003c/li\u003e\n\u003cli\u003eOng P, Camici PG, Beltrame JF, Crea F, Shimokawa H, Sechtem U, Kaski J C, Bairey Merz C N.International standardization of diagnostic criteria for microvascular angina[J].International Journal of Cardiology, 2018,250:16-20.\u003c/li\u003e\n\u003cli\u003eMa Guochao, Lin Chuanghui. Efficacy of extracorporeal stroke in patients with positive ECG exercise plate test [J]. Heilongjiang Medicine, 2020,33 (5): 1160-1162.\u003c/li\u003e\n\u003cli\u003eKonrad Stępień , Karol Nowak, Aleksandra Karcińska.,et al.Coronary Slow-Flow Phenomenon in Takotsubo Syndrome: The Prevalence, Clinical Determinants, and Long-Term Prognostic Impact[J].Int J Mol Sci, 2024,25(2):1297.\u003c/li\u003e\n\u003cli\u003eBradley C, Berry C.De fi nition and epidemiology of coronary microvascular disease [J].Nucl Cardiol ,2022, 29:1763\u0026ndash;75.\u003c/li\u003e\n\u003cli\u003eSucato V, Madaudo C, Galassi AR.Classi fi cation, diagnosis, and treatment of coronary microvascular dysfunction [J].Clin Med ,2022,11(15):4610.\u003c/li\u003e\n\u003cli\u003eSchindler TH, Dilsizian V.Coronary microvascular dysfunction: clinical considerations and noninvasive diagnosis [J].ACC Cardiovasc Imaging ,2020,13:140\u0026ndash;55.\u003c/li\u003e\n\u003cli\u003eChen C, Wei J, AlBadri A, Zarrini P, Bairey MC.Coronary microvascular d ysfunction epidemiology, pathogenesis, prognosis, diagnosis, risk factors and therapy [J].Circ J ,2016,81:3\u0026ndash;11.\u003c/li\u003e\n\u003cli\u003eDiagnostic criteria for coronary artery microangiopathy [J]. Clinical Journal of Traditional Chinese Medicine, 2023,35 (5): 1046-1047.\u003c/li\u003e\n\u003cli\u003eHu Gl. Progress in coronary microcirculatory disorders [J]. Journal of microcirculation, 2013,23 (4): 60-65.\u003c/li\u003e\n\u003cli\u003eMarija Zdravkovic, Viseslav Popadic , Slobodan Klasnja,et al .Coronary Microvascular Dysfunction and Hypertension: A Bond More Important than We Think[J].Medicina (Kaunas),2023,59(12):2149.\u003c/li\u003e\n\u003cli\u003eChen YL , Marc D Cook ,Heather Grimm,et al.The Effect of Race and Shear Stresson CRP Induced Responses in Endothelial Cells[J]. Mediators Inflamm,2021,11(2):11-18.\u003c/li\u003e\n\u003cli\u003eCaroline Dix, Johannes Zeller, Hannah Stevens,et al.C-reactive protein, immunothrombosis and venous thromboembolism[J].Review Front Immunol,2022, 13:1002652.\u003c/li\u003e\n\u003cli\u003ePau Ll\u0026agrave;cer , Fran\u0026ccedil;ois Croset, Rafael de la Espriella,et al.Trajectory of Urine Albumin-Creatinine Ratio in Patients with Acute Heart Failure[J].Cardiorenal Med,2024,14(1):74-80.\u003c/li\u003e\n\u003cli\u003eLinden MD, Jackson DE.Platelets: pleiotropic roles in atherogenesis and atherothrombosis[J].Int J Biochem Cell Biol,2010 ,42(11):1762-1766.\u003c/li\u003e\n\u003cli\u003eXia MY, Xu TL, Ni RZ,et al. Correlation analysis of C reactive protein to albumin ratio and neutrophil to lymphocyte ratio with coronary artery lesions in postmenopausal women [J]. The Chinese Cardiovascular Disease Study, 2023,21 (5): 390-396. \u003c/li\u003e\n\u003cli\u003eKhattab MH, Shahwan MJ, Hassan NAGM, Jairoun AA.Abnormal high-sensitivity C-reactive protein is Associated with an increased risk of Cardiovascular Disease and Renal Dysfunction among patients diagnosed with type 2 diabetes Mellitus in Palestine[J].Rev Diabet Stud.2022;18(1):27\u0026ndash;33.\u003c/li\u003e\n\u003cli\u003eYao SM, Zheng PP, Wan YH, Dong W, Miao GB, Wang H, Yang JF.Adding highsensitivity C-reactive protein to frailty assessment to predict mortality and cardiovascular events in elderly inpatients with cardiovascular disease[J].Exp Gerontol.2021;146:111235.\u003c/li\u003e\n\u003cli\u003eFeng G, Yang M, Xu L, Liu Y, Yu J, Zang Y, Shen S, Zheng X.Combined effects of high sensitivity C-reactive protein and triglyceride-glucose index on risk of cardiovascular disease among middle-aged and older Chinese: evidence from the China Health and Retirement Longitudinal Study, Nutr.[J].MetaCardiovasc Dis.2023;33(6):1245\u0026ndash;53.\u003c/li\u003e\n\u003cli\u003e.Chevli PA, Islam T, Pokharel Y, Rodriguez F, Virani SS, Blaha MJ, Bertoni AG, Budoff M, Otvos JD, Shapiro MD.Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the multi-ethnic study of atherosclerosis (MESA) [J].J Clin Lipidol.2022;16(6):870\u0026ndash;7.\u003c/li\u003e\n\u003cli\u003e.Kosmas CE, Martinez I, Sourlas A, Bouza KV, Campos FN, Torres V, Montan PD, Guzman E.High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease[J].Drugs Context.2018;7:212525.\u003c/li\u003e\n\u003cli\u003eLampka M, Olszewska-Słonina D, Hołyńska-Iwan I, Grąbczewska Z, Obońska K, Cwynar A, Stępowska J, Szewczyk-Golec K.Effect of low high-density lipopro tein level on endothelial activation and prothrombotic processes in coronary artery Disease-A Pilot Study[J].Int J Environ Res Public Health.2022;19(14):8637.\u003c/li\u003e\n\u003cli\u003eConstans J, Conri C.Circulating markers of endothelial function in cardiovascular disease [J].Clin Chim Acta.2006;368(1-2):33-47.\u003c/li\u003e\n\u003cli\u003eTretjakovs P, Lurins J, Svirskis S, Gersone G, Lurina D, Rozenberga U, Blumfelds L, Bahs G, Lejnieks A, Mackevics V. Thioredoxin-1 and Correlations of the Plasma Cytokines Regarding Aortic Valve Stenosis Severity[J]. Biomedicines. 2021 ,9(8):1041.\u003c/li\u003e\n\u003cli\u003eVerbovenko J, Bahs G.Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina[J].Clin Chim Acta ,2012,413(1-2):2529.\u003c/li\u003e\n\u003cli\u003eFeingold KR, Grunfeld C et al.The Effect of Inflammation and Infection on Lipids and Lipoproteins.In: Feingold KR, Anawalt B, Blackman MR, eds.Endotext[J].South Dartmouth (MA): MDText.com, Inc.; March 7, 2022.\u003c/li\u003e\n\u003cli\u003eBafei SEC, Zhao X, Chen C, etal.Sun JInteractive effect of increased high sensitive C-reactive protein and dyslipidemia on cardiovascular diseases: a 12-year prospective cohort study [J].Lipids Health Dis.2023 ,22(1):113.\u003c/li\u003e\n\u003cli\u003eGao Y, Wang M, Wang R, Jiang J, Hu Y, Wang W, Wang Y, Li H (2024) The predictive value of the hs-CRP/HDL-C ratio, an inflammation-lipid composite marker, for cardiovascular disease in middle-aged and elderly people: evidence from a large national cohort study [J].Lipids Health Dis 2024,23(1):66\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"C-reactive protein, high density liptein cholesterol, microvascular angina pectoris","lastPublishedDoi":"10.21203/rs.3.rs-4973475/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4973475/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eObjective\u003c/strong\u003e This study aimed to explore the relation ship between the serum ratio of C-reactive protein (CRP) to high density lip opro tein cholesterol (HDL-C) with microvascular angina(MVA).It also aimed to evaluate the predictive value of serum CRP /HDL-C in relation to MVA.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e The observation group consisted of 70 patients diagnosed with MVA ,while the control group included 68 patients with normal or minimal (\u0026lt; 50%) stenosis on coronary angiography, negative ECG exercise test and normal coronary blood flow randomly selected using a random number table method.Serum CRP,HCY,HDL-C and other relevant parameters were measured in both groups, with CRP /HDL-C calculated.Logistic regression analysis, and receiver operating characteristic (ROC) curve analysis were performed to identify independent risk factors for microvascular angina.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults \u003c/strong\u003eCRP/HDL-C levels were significantly elevated in MVA patients \u0026nbsp;with statistical significance (P \u0026lt; 0.001).The parameterswas identified as independent risk factor for predicting MVA occurrence.The results of ROC analysis indicated that CRP /HDL-C showed high predictive value for diagnosing MVA .The CRP/HDL-C had a higher area under the curve (AUC) for diagnosing microvascular angina compared to individual parameters ,with a statisticallysignificantdifference(P\u0026lt;0.05).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusions \u003c/strong\u003eElevated CRP /HDL-C levels can serve as positive predictors for diagnosing MVA.The parameters can enhance diagnostic accuracy and aid in the early identification of MVA patients..\u003c/p\u003e","manuscriptTitle":"The diagnostic value of serum C-reactive protein/high-density lipoprotein in microvascular angina","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-10-17 08:13:03","doi":"10.21203/rs.3.rs-4973475/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"15029d38-9361-42ef-b926-96af5dd5eec9","owner":[],"postedDate":"October 17th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2026-01-17T14:39:18+00:00","versionOfRecord":[],"versionCreatedAt":"2024-10-17 08:13:03","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4973475","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4973475","identity":"rs-4973475","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}